Physician profile
Robert Naples
NPI 1194187377
$3,342.37
in general payments reported to CMS, 2019-2025
17 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.46 · 2020: $16.91 · 2021: $150 · 2022: $26.42 · 2023: $1,535 · 2024: $1,038 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Education: $1,000 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.58 |
| Education | $1,000.00 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,028.98 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Dilon Technologies, INC. | $504.78 | 2023-2025 | Hemoblast Bellows |
| Momentis Surgical INC. | $500.00 | 2024 | Anova Surgical System |
| Boston Scientific Corporation | $402.77 | 2021-2023 | Spyglass Discover, Spyglass |
| Aroa Biosurgery Incorporated | $219.83 | 2024 | |
| Baxter Healthcare | $136.00 | 2025 | Floseal |
| Medtronic, INC. | $131.37 | 2025 | Signia |
| Solventum Corporation | $116.36 | 2024 | V.A.C.Instill, Abthera Advance, Prevena |
| Abbvie INC. | $86.98 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $36.62 | 2019 | |
| Lundbeck LLC | $34.62 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $32.76 | 2025 | Trelegy Ellipta |
| Integra Lifesciences Corporation | $26.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.84 | 2019 | |
| Merck Sharp & Dohme LLC | $23.11 | 2024 | Dificid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.02 | 2023 | Livalo |
| Teva Pharmaceuticals USA, INC. | $16.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Naples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.